Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer.
CONCLUSIONS: pTULSA appears safe and feasible for palliative ablation of locally advanced prostate cancer. The therapy seems to accomplish long-term hematuria control, can relieve bladder outlet obstruction in selected patients, and seems to reduce the burden of hospitalization due to local complications. Trial Registration Number: NCT03350529. PMID: 32897169 [PubMed - as supplied by publisher]
CONCLUSIONS: Triamcinolone bladder neck injections for post-RP VUAS are a useful and safe treatment for recurrent stenosis. PMID: 32807289 [PubMed - as supplied by publisher]
A 49-year-old male with a history of locally advanced small cell prostate cancer presents with new-onset medically refractory constipation prompting concerns of impending bowel obstruction. Five months earlier, the patient had been diagnosised with stage IVA (T4N1M0) high-grade neuroendocrine carcinoma of the prostate during a workup for recurrent urinary tract infections, hydronephrosis, and sepsis. Palliative bilateral percutaneous nephrostomy tubes were placed. Staging with positron emission tomography/computed tomography (PET/CT) revealed a 9.7 × 12.0 × 13.0 cm heterogeneously enhancing prostatic mass invol...
Radiation-cystitis is an unavoidable side effect of external beam radiation therapy to the pelvis, even when delivered using normal tissue sparing delivery methods such as image guided radiation therapy (IGRT) and volumetric modulated arc therapy (VMAT). Cystitis symptoms include dysuria, urinary frequency, urgency, nocturia, the sensation of incomplete bladder voiding, haematuria and an increased risk of urinary tract infections. Acute radiation-cystitis develops during radiation therapy and generally resolves within weeks of completing radiation treatment.
ConclusionFocal salvage HIFU conferred a relatively low complication and side effect rate. CEFS and biochemical control in the short to medium term were reasonable, especially in this relatively high‐risk cohort, but still low compared with current whole‐gland salvage therapies. Focal salvage therapy may offer disease control in men at high risk whilst minimizing additional treatment morbidities.
ConclusionsPAE is a safe and feasible for the relief of LUTS and IBC in highly comorbid patients without surgical treatment options.
We report a case of posterior bladder neck disruption as a complication of a robotic assisted laparoscopic prostatectomy that presented to the emergency department as dysuria and abdominal pain following urination.
Benign prostatic hyperplasia (BPH), or enlargement of the prostate gland, affects about half of men between the age of 51 and 60 and up to 90% of men over the age of 80. Symptoms include difficulty with initiating urination, weak urine flow, post-voi...
This article give a brief account of rationale and efficacy of various existing phytotherapeutic agents in the management of benign prostatic hyperplasia, including the herbs which hold the potential promise are also mentioned , although much research is still required. PMID: 27337973 [PubMed - as supplied by publisher]
CONCLUSIONSAlisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21‐day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33. © 2016 American Cancer Society.
CONCLUSIONSAlisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21‐day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016. © 2016 American Cancer Society.